What is the recommended daily intake of manganese, how does deficiency present, and how is manganese toxicity managed?

Manganese: Daily Intake, Deficiency, and Toxicity Management

For adults, provide 2-3 mg manganese daily through enteral nutrition, but in parenteral nutrition, limit manganese to 55 µg/day (1 µmol/day) to prevent irreversible neurotoxicity, particularly manganism—a Parkinson-like syndrome that represents a far greater clinical concern than the exceptionally rare deficiency states. 1

Recommended Daily Intake

Oral/Enteral Nutrition

• Adults: 2.3 mg/day for men, 1.8 mg/day for women (Institute of Medicine adequate intake) 1
• Enteral nutrition formulations: 2-3 mg/day, with doses up to 6 mg/day considered safe in 1500 kcal 1
• Upper tolerable limit: 11 mg/day for dietary intake 1

Dietary sources include whole grains, shellfish (clams, oysters, mussels), nuts, soybeans, legumes, rice, leafy vegetables, coffee, tea, and spices like black pepper 1

Parenteral Nutrition

• Critical recommendation: 55 µg/day (1 µmol/day) maximum 1
• Contamination limit: <40 µg/day total in adult PN formulas 1
• Avoid doses: IV intakes of 110 µg/day (2 µmol/day) are excessive and cause elevated blood manganese 1

The stark difference between oral and IV dosing exists because dietary absorption is tightly regulated by the gut (only 2-10% absorbed), while IV administration bypasses all homeostatic mechanisms 1

Manganese Deficiency

Manganese deficiency is exceptional in humans and clinically insignificant—only 2.1% of critically ill patients show decreased values, with no relationship to clinical outcomes. 1

Theoretical Manifestations (from experimental studies)

When deficiency has been experimentally induced:

• Transient skin rash
• Decreased serum cholesterol
• Elevated alkaline phosphatase, calcium, and phosphorus
• Altered mood and increased premenstrual pain in women 1

In animal models (not reliably translatable to humans): impaired growth, skeletal defects, abnormal glucose tolerance, altered lipid/carbohydrate metabolism 1

Clinical pearl: The rarity of deficiency means you should not routinely supplement manganese without clear indication, especially given toxicity risks.

Manganese Toxicity

Toxicity is the primary clinical concern with manganese—the brain is the main target organ, and neurological damage may be irreversible. 1

High-Risk Populations

Monitor manganese levels in patients with:

• Long-term parenteral nutrition (>30 days, intake >55 µg/day) 1
• Hepatobiliary dysfunction (cholestasis, liver failure, hepatic encephalopathy)—manganese is excreted in bile 1
• Iron deficiency—competing transport proteins lead to manganese accumulation 1
• Renal disease
• Vegetarian diet (high dietary manganese)
• SLC30A10 genetic mutations 2

Clinical Presentation

Early (non-specific) symptoms:

• Headache
• Asthenia (weakness)
• Irritability
• Fatigue
• Muscular pains 1

Late-stage manganism (neurodegenerative syndrome):

• Cognitive deficits
• Motor dysfunction (Parkinson-like)
• Emotional/psychiatric symptoms
• Progressive and potentially irreversible 1

Somatic effects:

• Hypertension and increased heart rate (calcium channel blockade)
• Elevated cholesterol (reduced conversion to bile acids)
• Decreased male fertility
• Increased fetal abnormalities 1

Diagnostic Approach

When to measure: Suspect toxicity in long-term PN patients (>30 days), those with liver dysfunction, or iron deficiency 1

Monitoring frequency: No more often than 40-day intervals (biological half-life) 1

Laboratory testing:

• Whole blood or RBC manganese (preferred)—majority of circulating manganese is in erythrocytes 1
• Measure by ICP-MS or atomic absorption spectroscopy 1
• Treatment threshold: Whole blood values >2× upper limit of normal 1

Imaging:

• Brain MRI: High-intensity signals in globus pallidus correlate with elevated manganese levels and confirm diagnosis 1

Management of Manganese Toxicity

Step 1: Remove the source

• Immediately eliminate manganese from PN admixture 1
• Discontinue any manganese-containing additives 1

Step 2: Pharmacological interventions

• Iron supplementation if iron deficiency present (corrects competitive transport protein binding) 1
• Chelation therapy: EDTA or para-aminosalicylic acid (PAS)—variable success 1
• Future consideration: Stem cell therapy (experimental) 1

Critical caveat: Due to neuronal cell death in basal ganglia, functional recovery is limited even with treatment. Prevention is paramount. 1

Prevention Strategies in Parenteral Nutrition

Practical algorithm:

1. Use individual trace element additives rather than fixed multi-trace formulations when possible
2. Limit manganese to 55 µg/day maximum in PN 1
3. Ensure contamination <40 µg/day total 1
4. Monitor whole blood manganese every 40+ days in long-term PN patients 1
5. Consider eliminating manganese entirely from PN in patients with cholestasis, liver disease, or prolonged PN duration 2, 3
6. Correct iron deficiency promptly to prevent manganese accumulation 1

Important note: Toxicity has been observed with IV doses as low as 110 µg/day, and in some cases within just 15 days of supplementation 1, 2. The historical practice of providing 55-550 µg/day in PN formulations was excessive and dangerous.